West Pharmaceutical Services (NYSE:WST) Releases FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 6.000-6.200 for the period, compared to the consensus estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Price Performance

Shares of WST stock traded up $15.73 on Monday, hitting $214.84. 5,020,477 shares of the stock traded hands, compared to its average volume of 424,824. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.00 and a quick ratio of 2.23. West Pharmaceutical Services has a 52 week low of $197.01 and a 52 week high of $400.88. The firm has a 50 day simple moving average of $327.86 and a two-hundred day simple moving average of $313.97. The firm has a market cap of $15.56 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 19.31 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The business had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million. As a group, equities research analysts predict that West Pharmaceutical Services will post 6.67 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, February 11th. Investors of record on Friday, February 7th were issued a $0.21 dividend. The ex-dividend date of this dividend was Friday, February 7th. This represents a $0.84 dividend on an annualized basis and a yield of 0.39%. West Pharmaceutical Services's dividend payout ratio is presently 12.46%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on WST. Bank of America upped their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. UBS Group raised shares of West Pharmaceutical Services from a "neutral" rating to a "buy" rating and raised their target price for the company from $350.00 to $390.00 in a report on Thursday, December 12th. StockNews.com upgraded shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a report on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 price target for the company in a research report on Friday. Finally, Wolfe Research assumed coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They issued a "peer perform" rating for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $344.00.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.